Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy

Clinical Therapeutics

Volumn 26, Issue 11, 2004, Pages 1783-1790

  McCluskey, Dennis ^a,c   Scott Touger, M ^b   Melis, Robert ^c,d   Schleusener, Debra S ^c  

^a Ohio   (United States)

^b Bridgewater New Jersey USA ^*  (United States)

^c SANOFI   (France)

^d Aventis Pharmaceuticals   (United States)

Author keywords

Glimepiride; Glycemic control; Glycosylated hemoglobin (HbA1e); Rosiglitazone

Indexed keywords

GLIMEPIRIDE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCOSYLATION; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TITRIMETRY;

ADULT; AGED; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 11844271546     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.11018     Document Type: Article

References (16)

1. Wysowski D.K., Armstrong G., and Govemale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001 Diabetes Care 26 2003 1852 1855
2. American Association of Clinical Endocrinologists and American College of Endocrinology The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self- management 2002 update Endocr Pract. 8 Suppl 1 2002 40 82
3. Rendell M.S., Glazer N.B., and Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: Influence of prior antidiabetic drug regimen J Diabetes Complications 17 2003 211 217
4. Kipnes M.S., Krosnick A., and Rendell M.S. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study Am J Med. 111 2001 10 17
5. Korytkowski M., Thomas A., and Reid L. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes Diabetes Care 25 2002 1607 1611
6. Schade D.S., Jovanovic L., and Schneider J. A placebocontrolled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful J Clin Pharmacol 38 1998 636 641
7. 1c without weight gain in patients with type 2 diabetes treated with glimepiride, both alone and in combination therapies Diabetes 51 Suppl 2 2002 A606
8. Abstract 1355 Charpentier G., Jolchine I.E., and Kabir M. Addition of glimepiride significantly improves glycemic control in type 2 diabetic patients insufficiently controlled on metformin Diabetes 47 Suppl 1 1998 A351
9. Patel J., Anderson R.J., and Rappaport E.B. Rosightazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study Diabetes Obes Metab. 1 1999 165 172
10. Wolffenbuttel B.E.E., Gomis R., and Squatrito S. Addition of low- dose rosightazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients Diabet Med. 17 2000 40 47
11. American Diabetes Association Standards of medical care in diabetes Diabetes Care 27 Suppl 1 2004 S15 S35
12. Charpentier G., Fleury F., and Kabir M. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients Diabet Med. 18 2001 828 834
13. Sahi J., Black C.B., and Hamilton G.A. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition Drug Metab Dispos. 31 2003 439 446
14. Idris I., Gray S., and Donnelly R. Rosightazone and pulmonary oedema: An acute dose-dependent effect on human endothelial cell permeability Diabetologia. 46 2003 288 290
15. Nesto R.W., Bell D., and Bonow R.W. American Heart Association; American Diabetes Association Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 108 2003 2941 2948
16. Fonseca V., Grunberger G., and Gupta S. Addition of nateglinide to rosightazone monotherapy suppresses mealtime hyperglycemia and improves over all glycemic control Diabetes Care 26 2003 1685 1690